Great Novel Therapeutics Biotech and Medicals Corporation (GNTbm) focuses on innovative oral new drug development for the treatment of advanced and refractory cancers. GNTbm is devoted to cancer immunotherapy, ranging from epigenetic modulators, tumor microenvironment regulators (TMRs) of new drug combinations, epigenetic immunoactivators, and immunoregulatory multi-kinase inhibitors, which can be applied to treat varieties of cancers and to meet the clinical needs of advanced and refractory cancers worldwide.
The main R&D core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunoactivator platform, and the immunoregulatory multiple-kinase inhibitor platform, are applied to the development of new drugs with innovative mechanisms in cancer immunotherapy. These oral innovative immune-regulating new drugs can activate the patient's immune system, remodel the tumor microenvironment, stimulate CTL to recognize and attack the tumor, and induce lasting immune memory, which can effectively improve the therapeutic benefits for patients with advanced and refractory cancers .
On the other hand, GNTbm has developed the new generation epigenetic modulator--- Tucidinostat (Chidamide) for the treatment of HR+/Her-2- advanced breast cancer, peripheral T-cell lymphoma, hepatocellular carcinoma (HCC) and other new cancers.
GNTbm independently develops new chemical entity (NCE) new drugs with innovative mechanisms and new drug combinations for cancer immunotherapy with better safety and superior efficacy, aiming at providing the unmet clinical needs of patients with advanced and refractory cancers.
Overview
Business Model
.jpg)
Vision
Cancer is a major life-threatening disease. How to meet the treatment needs of patients with advanced and refractory cancers and give patients the opportunity to achieve lasting clinical benefits is the goal pursued by GNTbm. GNTbm's in-house new drug R&D mainly focuses on the field of cancer immunotherapy and development of oral new drugs with novel structures and innovative mechanisms, including epigenetic immunoactivators and immunoregulatory multi-kinase inhibitors, designs new drug combinations to enhance tumor microenvironment regulation, and is committed to solving the urgent treatment needs of advanced and refractory cancer patients.
Through continuous innovation of technology and optimization of R&D platform, GNTbm applies these new drugs alone or in combination to maximize their effectiveness in the field of cancer immunotherapy, providing more efficacious, longer-lasting, and safer treatment options, and improving quality of life for patients with advanced and refractory cancers.
Mission
GNTbm's mission is to be a pioneer in the field of immuno-oncology. R&D pipeline includes innovative epigenetic immunoactivators and immunoregulatory multi-kinase inhibitors, and novel combination of these new drugs, for the regulation and remodeling of tumor microenvironment, with the goal of activating patient's immune system for the eradiation of tumor.
Based in Taiwan, but with a global focus, GNTbm is committed to immune-regulating research and drug development, which will give our company a place on the world stage in the field of cancer immunotherapy.
